Why Is ALNYLAM PHARMACEUTIC (ALNY) Stock Moving Today?

ALNY stock fell 5.54% to $267.47 in a session marked by a broader reaction to a major Phase 3 trial failure in the biotech sector. The decline came as investors digested the news that Wainua missed its Phase 3 endpoint, which disproportionately hurt Ionis Pharmaceuticals while benefiting rivals such as AstraZeneca, BridgeBio, and Alnylam Pharmaceuticals. The stock’s move reflects shifting sentiment in the sector and a reevaluation of relative risk exposure.

What Happened

The failure of Wainua’s Phase 3 trial triggered a reallocation of investor capital within the biotech space. Alnylam Pharmaceuticals, which had previously faced scrutiny for its own late-stage development risks, saw its stock fall as the broader market recalibrated. The decline in ALNY came despite the company’s strong fundamentals, including a trailing twelve-month revenue growth of 82.6% and a net margin of 12.5%. A single insider transaction was reported on June 1, when David E. Pyott, a director, sold shares. The broader market response was amplified by the fact that AstraZeneca was able to absorb the blow of Wainua’s failure more easily, shifting capital to perceived safer or more promising alternatives.

What The Data Shows

ALNY traded near its 52-week low of $266.43, indicating a sharp correction from its recent performance. The stock’s beta of 0.27 suggests it is less volatile than the broader market, yet it has seen a significant drop in sentiment, with its 7-day average falling to 49 out of 100 from a 30-day average of 60. Over the past 90 days, insiders sold $1.1 million worth of shares, with no buy transactions reported. Meanwhile, recent congressional trades by Donald J. Trump included both purchases and sales in the $1,001, $15,000 range, with the most recent sale disclosed on July 1.

What To Watch

The stock is currently trading near its 52-week low and will be closely watched for signs of stabilization. No earnings date was provided in the data, but coverage breadth and insider activity will remain key indicators for near-term direction.

Why is ALNY stock moving today?

ALNYLAM PHARMACEUTIC (ALNY) is drawing unusual attention today. Our newswire has captured 1 story on ALNY across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 68/100). The most recent driver: "Alnylam Pharmaceuticals Q2 2026 Earnings Preview" (Seeking Alpha).

Is ALNY a buy right now?

Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of ALNY coverage reads 68/100 over 1 stories; treat it as a research signal and do your own diligence.

How fast does this page update?

The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.